1 | Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. (Flume PA, Biner RF, Downey DG, Brown C, Jain M, Fischer R, De Boeck K, Sawicki GS, Chang P, Paz-Diaz H, Rubin JL, Yang Y, Hu X, Pasta DJ, Millar SJ, Campbell D, Wang X, Ahluwalia N, Owen CA, Wainwright CE, VX14-661-110 study group) Lancet Respir Med 2021 Jul;9(7):733-746 33 Citations |
1 | Lumacaftor/ivacaftor therapy fails to increase insulin secretion in F508del/F508del CF patients. (Moheet A, Beisang D, Zhang L, Sagel SD, VanDalfsen JM, Heltshe SL, Frederick C, Mann M, Antos N, Billings J, Rowe SM, Moran A, PROSPECT Investigators of the Cystic Fibrosis Foundation Therapeutics Development Network) J Cyst Fibros 2021 Mar;20(2):333-338 38 Citations |
1 | Severe parkinsonism caused by brexpiprazole: A case report. (Jackowiak EM, Chou KL) Parkinsonism Relat Disord 2019 Dec;69:138-139 1 Citation |
2 | Cyclic AMP regulates the migration and invasion potential of human pancreatic cancer cells. (Zimmerman NP, Roy I, Hauser AD, Wilson JM, Williams CL, Dwinell MB) Mol Carcinog 2015 Mar;54(3):203-15 44 Citations |
2 | Activation of dimeric ABA receptors elicits guard cell closure, ABA-regulated gene expression, and drought tolerance. (Okamoto M, Peterson FC, Defries A, Park SY, Endo A, Nambara E, Volkman BF, Cutler SR) Proc Natl Acad Sci U S A 2013 Jul 16;110(29):12132-7 231 Citations |
1 | BK virus in the kidney transplant patient. (Kuppachi S, Thomas B, Kokko KE) Am J Med Sci 2013 Jun;345(6):482-8 |
1 | Tumor marker and measurement fluctuations may not reflect treatment efficacy in patients with medullary thyroid carcinoma on long-term RET inhibitor therapy. (Kurzrock R, Atkins J, Wheler J, Fu S, Naing A, Busaidy N, Hong D, Sherman S) Ann Oncol 2013 Sep;24(9):2256-61 26 Citations |
1 | Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies. (Hong DS, Cabanillas ME, Wheler J, Naing A, Tsimberidou AM, Ye L, Busaidy NL, Waguespack SG, Hernandez M, El Naggar AK, Bidyasar S, Wright J, Sherman SI, Kurzrock R) J Clin Endocrinol Metab 2011 Apr;96(4):997-1005 91 Citations |
1 | Farnesyltransferase inhibitors: where are we now? (Tsimberidou AM, Chandhasin C, Kurzrock R) Expert Opin Investig Drugs 2010 Dec;19(12):1569-80 37 Citations |
1 | Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. (Hong DS, Sebti SM, Newman RA, Blaskovich MA, Ye L, Gagel RF, Moulder S, Wheler JJ, Naing A, Tannir NM, Ng CS, Sherman SI, El Naggar AK, Khan R, Trent J, Wright JJ, Kurzrock R) Clin Cancer Res 2009 Nov 15;15(22):7061-8 79 Citations |
1 | Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. (Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen PR, Diwan AH, Evans HL, Kurzrock R) Arch Dermatol 2008 Jun;144(6):779-82 45 Citations |
1 | Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. (Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock R) Mol Cancer Ther 2008 May;7(5):1001-6 50 Citations |
1 | Phase I study of alternate-week administration of tipifarnib in patients with myelodysplastic syndrome. (Kurzrock R, Kantarjian HM, Blascovich MA, Bucher C, Verstovsek S, Wright JJ, Pilat SR, Cortes JE, Estey EH, Giles FJ, Beran M, Sebti SM) Clin Cancer Res 2008 Jan 15;14(2):509-14 19 Citations |
1 | Vasopressin-induced nitric oxide production in rat inner medullary collecting duct is dependent on V2 receptor activation of the phosphoinositide pathway. (O'Connor PM, Cowley AW Jr) Am J Physiol Renal Physiol 2007 Aug;293(2):F526-32 24 Citations |
1 | A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. (Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian H, Cripe L, Kerstens R, De Porre P, Kurzrock R) Blood 2007 May 15;109(10):4158-63 104 Citations |
1 | Farnesyltransferase inhibitors. (Kurzrock R) Clin Adv Hematol Oncol 2005 Mar;3(3):161-2 7 Citations |
1 | Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. (Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G, Thomas DA, Giles FJ, Ryback ME, Thibault A, De Porre P, Kantarjian HM) J Clin Oncol 2004 Apr 01;22(7):1287-92 149 Citations |
1 | Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. (Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF, Wright JJ, Freireich EJ, Talpaz M, Sebti SM) Blood 2003 Dec 15;102(13):4527-34 129 Citations |
1 | Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. (Cortes J, Albitar M, Thomas D, Giles F, Kurzrock R, Thibault A, Rackoff W, Koller C, O'Brien S, Garcia-Manero G, Talpaz M, Kantarjian H) Blood 2003 Mar 01;101(5):1692-7 215 Citations |
1 | Pharmacophore/receptor models for GABA(A)/BzR subtypes (alpha1beta3gamma2, alpha5beta3gamma2, and alpha6beta3gamma2) via a comprehensive ligand-mapping approach. (Huang Q, He X, Ma C, Liu R, Yu S, Dayer CA, Wenger GR, McKernan R, Cook JM) J Med Chem 2000 Jan 13;43(1):71-95 165 Citations |